PharmEnable utilizes AI-driven methodologies to identify novel chemical starting points for small molecule therapeutics, specifically targeting challenging conditions in cancer and neurological diseases. This approach enhances the specificity of drug design, enabling the discovery of effective treatments for previously inaccessible biological targets.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MHFounders
Product
Problem
Traditional small molecule drug discovery faces challenges in identifying novel chemical starting points, particularly for complex biological targets in cancer and neurological diseases. Existing compound libraries often lack the structural diversity and complexity needed to effectively engage these targets, leading to high attrition rates in clinical trials.
Solution
PharmEnable utilizes an AI-enabled drug discovery platform to design novel, structurally complex small molecule therapeutics, addressing previously inaccessible biological targets. The platform, incorporating chemUniverse and chemSeek AI, explores underexplored regions of chemical space to identify molecules with enhanced tridimensionality and drug-like properties. By focusing on diversity and complexity, PharmEnable aims to create highly specific drug candidates with improved selectivity and reduced off-target effects. This approach facilitates the development of effective treatments for challenging conditions in cancer, neurological diseases, and viral infections.
Target Audience
PharmEnable's primary customers are pharmaceutical companies and research organizations focused on developing small molecule therapeutics for cancer, neurological diseases, and viral infections, particularly those targeting complex or previously undruggable targets.
Features
- chemUniverse: A diversity-focused virtual database of chemically diverse molecules.
- chemSeek: A suite of AI-enabled tools for identifying drug target matches from structure and ligand data.
- AI-driven platform for exploring underexplored chemical space.
- Design of novel small molecules with 3D structures and complexity similar to natural compounds.
- Identification of hits with improved specificity compared to traditional screening methods.
- Focus on challenging biological targets, including protein-protein interactions and GPCRs.
- Capabilities for structure-based drug design (SBDD) through collaborations.